Literature DB >> 8970969

Analysis of the human env-specific cytotoxic T-lymphocyte (CTL) response in natural human immunodeficiency virus type 1 infection: low prevalence of broadly cross-reactive env-specific CTL.

A Carmichael1, X Jin, P Sissons.   

Abstract

Major histocompatibility complex-restricted cytotoxic T lymphocytes (CTL) are part of the cellular immune response to persistent virus infections. Candidate vaccines against human immunodeficiency virus type 1 (HIV-1) should elicit broad cross-reactive immunity to confer protection against different strains of HIV-1. As it is likely that candidate vaccines will include the envelope gene product Env, we determined the proportion of CTL clones which recognized variable and conserved determinants in three env variants during natural infection. Limiting dilution analysis was used to characterize numerous short-term CTL clones derived from peripheral blood of HIV-1-infected subjects, using split-well analysis to assay cytotoxicity against target cells expressing gp160env of HIV-1 strains IIIB, MN, and RF. In 9 of 12 HIV-1-infected subjects, at the clonal level most env-specific CTL recognized determinant(s) within one env variant but not in the other variants. In some subjects, CTL recognized multiple nonconserved determinants in different variants. The pattern of recognition of different env variants was relatively stable over time. In most of the patients studied, the proportion of CTL which showed cross-recognition of conserved determinants shared among the three strains was low. Two novel CTL epitopes within gp41 were identified by using 15-mer peptides of the HIV-SF2 sequence. When specific peptide was used to stimulate CTL precursors in vitro, the frequency of peptide-specific CTL precursors was very high, but the CTL elicited by this stimulation were highly strain specific. We conclude that the use of a single HIV env variant to detect CTL activity can underestimate the magnitude and complexity of the env-specific CTL response. The low prevalence of CTL clones which show cross-recognition of conserved determinants may have implications for immunization strategies based solely on env; to elicit broadly cross-reactive CTL other, more conserved viral antigens are likely to be needed in addition to env. Because of its capacity to distinguish CTL responses against different virus strains, limiting dilution analysis is particularly appropriate to quantitate the immune responses generated by candidate env-based vaccines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8970969      PMCID: PMC190937     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations.

Authors:  A Meyerhans; R Cheynier; J Albert; M Seth; S Kwok; J Sninsky; L Morfeldt-Månson; B Asjö; S Wain-Hobson
Journal:  Cell       Date:  1989-09-08       Impact factor: 41.582

2.  Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual.

Authors:  S Koenig; P Earl; D Powell; G Pantaleo; S Merli; B Moss; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

3.  Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans.

Authors:  A Hoffenbach; P Langlade-Demoyen; G Dadaglio; E Vilmer; F Michel; C Mayaud; B Autran; F Plata
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

4.  HIV vaccines. Back to primary school.

Authors:  J P Moore
Journal:  Nature       Date:  1995-07-13       Impact factor: 49.962

Review 5.  The evaluation of limiting dilution assays.

Authors: 
Journal:  J Immunol Methods       Date:  1982-03-12       Impact factor: 2.303

6.  CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity.

Authors:  M J Reddehase; W Mutter; K Münch; H J Bühring; U H Koszinowski
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

7.  Phenotypic heterogeneity of cerebrospinal fluid-derived HIV-specific and HLA-restricted cytotoxic T-cell clones.

Authors:  K K Sethi; H Näher; I Stroehmann
Journal:  Nature       Date:  1988-09-08       Impact factor: 49.962

8.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.

Authors:  J Albert; B Abrahamsson; K Nagy; E Aurelius; H Gaines; G Nyström; E M Fenyö
Journal:  AIDS       Date:  1990-02       Impact factor: 4.177

9.  HIV-specific cytotoxic T lymphocytes in seropositive individuals.

Authors:  B D Walker; S Chakrabarti; B Moss; T J Paradis; T Flynn; A G Durno; R S Blumberg; J C Kaplan; M S Hirsch; R T Schooley
Journal:  Nature       Date:  1987 Jul 23-29       Impact factor: 49.962

10.  Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins.

Authors:  Y Riviere; F Tanneau-Salvadori; A Regnault; O Lopez; P Sansonetti; B Guy; M P Kieny; J J Fournel; L Montagnier
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

View more
  2 in total

1.  Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients.

Authors:  D Durali; J Morvan; F Letourneur; D Schmitt; N Guegan; M Dalod; S Saragosti; D Sicard; J P Levy; E Gomard
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

2.  Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy.

Authors:  M Dalod; M Dupuis; J C Deschemin; D Sicard; D Salmon; J F Delfraissy; A Venet; M Sinet; J G Guillet
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.